Early‐Onset Posterior Reversible Encephalopathy Syndrome at Reduced‐Dose Sunitinib in Metastatic Papillary Renal Cell Carcinoma: A Case Report
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare but potentially life‐threatening neurological complication associated with vascular endothelial growth factor (VEGF)‐targeted tyrosine kinase inhibitors. Although it is typically reported after prolonged exposure and at standard or high doses, early onset at reduced dosing may occur and requires prompt recognition. We report a 64‐year‐old woman with metastatic papillary renal cell carcinoma who developed PRES after two months of treatment with reduced‐dose sunitinib (37.5 mg daily). She presented with severe headache, nausea, vomiting, impaired consciousness, and reduced mobility, accompanied by acute hypertension (170/100 mmHg). Brain magnetic resonance imaging demonstrated bilateral vasogenic edema without diffusion restriction, consistent with PRES, and electroencephalography revealed generalized background slowing indicative of encephalopathy. Sunitinib was immediately discontinued, and the patient was treated with corticosteroids, antiepileptic therapy, and antihypertensive agents, resulting in rapid clinical improvement. Follow‐up imaging confirmed complete radiological resolution. Subsequent treatment with nivolumab and axitinib achieved limited disease control, and the overall survival was 11 months. This case highlights that PRES can develop early and at reduced doses of sunitinib, may present with severe neurological impairment, and can be supported by electroencephalographic findings. Early recognition…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.